Introduction: The prescribing information for
at 30 days. The exposure of interest was use of statins. The primary outcome was CPK elevation defined as a CPK value C3 times the upper limit of normal (ULN) if baseline CPK was normal, and C5 times ULN if baseline CPK was elevated. The secondary outcome was death within 30 days of commencing daptomycin.
Results: A total of 233 patients were included in this analysis. Among these patients, 53 received concomitant statin therapy. Most baseline clinical characteristics were similar between statin recipients and non-recipients. 
INTRODUCTION
Daptomycin is an antibiotic used to treat complicated infections caused by aerobic Gram-positive organisms, including methicillin-resistant Staphylococcus aureus
(MRSA) and vancomycin-resistant Enterococcus (VRE) [1] . The use of this agent has somewhat been limited by its toxicity profile, specifically the potential to cause elevations in creatine phosphokinase (CPK) [1] . This is a meaningful outcome as CPK elevation may be indicative of skeletal muscle toxicity and, in extreme circumstances, life-threatening conditions such as rhabdomyolysis [2] . The potential to cause elevations in CPK may be enhanced when daptomycin exposure is altered (e.g., higher doses or diminished creatinine clearance) [3] or when used in combination with other agents that also increase CPK [1] . [6] .
Statin Exposure
The exposure of interest in this study was the use of statin therapy while receiving daptomycin. The specific statins that were available during the study period were:
simvastatin, atorvastatin, pravastatin, rosuvastatin, lovastatin, fluvastatin and pitavastatin.
Outcomes
The outcomes examined were: (1) CPK elevation and (2) 
Statistical Analyses
In the bivariate analyses, categorical variables were assessed using Chi square and Fisher's exact test. For continuous variables, Student's T and Mann-Whitney U tests were used. The log-rank test was used to compare frequency of CPK elevations, integrated over time, between statin recipients and non-recipients. Stratified analyses were performed to assess for effect modification. Stratum-specific measures of association were compared using the BreslowDay test. All analyses were performed using SPSS (IBM, v21.0, Chicago, USA) and SAS (SAS Institute, v9.1, Cary, USA).
RESULTS
There were 350 patients who received daptomycin at a VISN-2 facility. There were 117 patients that were excluded because they did not receive daptomycin for C48 h or did not have a CPK level measurement taken while on therapy. Among the 233 patients that met inclusion criteria, 180 received daptomycin alone and 53 received daptomycin while receiving a statin.
The demographics and clinical characteristics of the study population are displayed in Table 1 . Overall, the majority of these baseline characteristics were similar between the two groups. Mean ± standard deviation (SD) age was higher (p = 0.02) for statin recipients (69.7 ± 9.8) than nonrecipients (65.1 ± 13.0). Mean ± SD APACHE-II scores were also higher (p = 0.04) in statin recipients (13.9 ± 7.3) than non-recipients (11.6 ± 6.8). Patients with a higher degree of renal dysfunction at baseline were more likely to receive daptomycin while receiving a statin. With regard to daptomycin use, there were no statistically significant differences observed in dose and duration of daptomycin therapy between groups. Study outcomes are described in Table 2 . Elevations in CPK levels were observed in a total of five patients (2.1%). Among these five patients, 3/53 (5.7%) patients received daptomycin while receiving a statin, and 2/180 (1.1%) received daptomycin alone (p = 0.08). No effect modification was observed by use of other concomitant medications known to increase CPK values. In the time-toevent analyses, there was no significant difference in CPK elevation over time between statin recipients and non-recipients (p = 0.14).
All patients that had a CPK elevation had a normal baseline CPK value. Baseline creatinine clearance also did not affect the development of 
DISCUSSION
We performed a retrospective cohort study of Veterans' Affairs patients that received daptomycin therapy to assess the relationship between concomitant statin therapy and CPK elevation. We observed no significant difference [7] and Bhavnani et al. [3] ),
there was a lower incidence (2.2%) of CPK elevation observed than previously reported in the literature [8] [9] [10] , irrespective of whether daptomycin was given with or without a statin.
Bhavnani et al. examined the probability of CPK elevations in patients who received daptomycin without a statin and determined the predicted probability of a CPK elevation to be between 3.73% and 19.5% (at doses ranging from 4 to [3] . It is interesting to note that the median (IQR) daptomycin dose in our study was 6.0 (5.5-6.3) mg/kg and is similar to the actual dose (6 mg/kg) administered to patients in the bacteremia/endocarditis registration trial [7] and the simulations performed by Bhavnani et al. [3] . The lower frequency of CPK elevations may denote competing risks or an etiology that involves varying contributions of exposure, severity of illness and other clinical factors.
The results of our study are generally consistent with recently published data regarding lack of a statistically significant relationship between CPK elevations and concomitant use of daptomycin and statin therapy [2, [8] [9] [10] . Parra-Ruiz et al. reported an 8% occurrence of CPK elevation with the combination of high-dose ([6 mg/kg/day) daptomycin and statin therapy, and a 10% occurrence of CPK elevation in patients receiving daptomycin only [6] . While the point estimates are higher than those in our analysis, the comparison resulting in no difference between the two treatment groups is largely consistent.
Our study suggests that the incidence of CPK elevation may be less frequent than previously reported. This is an interesting finding given that the population studied included patients that received care at a VISN-2 facility. The
Veterans' Affairs population is primarily made up of patients with a larger distribution of comorbidities than the general population [11] .
Given their underlying health status, this is a population that one would expect to have a higher frequency of CPK elevations [12] . These findings have important implications for utilization of daptomycin since it may not be as toxic as previously perceived, regardless of whether used concomitantly with statin therapy. Future studies should assess the risk of CPK elevation in non-VA Medical Center settings where the volume of comorbidities is less pronounced.
Although not found to be statistically significant, daptomycin patients receiving a Finally, none of the CPK events occurred in patients on hemodialysis. This is an important point to consider because these patients are likely to have altered drug exposure and potentially have a higher probability of achieving troughs in excess of 24.3 lg/mL, the threshold associated with an elevated risk of CPK elevations [3] . Given that this trough target was derived from patients enrolled in registration trials of daptomycin, future studies should evaluate if this trough threshold is applicable to the general population of patients using daptomycin and if the threshold differs by use of concomitant statin therapy, hemodialysis and other clinical factors that may modify daptomycin exposure.
In summary, the incidence of CPK elevation did not significantly differ with or without concomitant statin therapy among patients 
